TY  - CONF
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
AU  - Miljković, Branislava
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3826
AB  - Background Exposure to anticholinergic and sedative drugs have been associated with adverse health outcomes in the elderly population, which can be measured in an individual patient using Drug Burden Index (DBI). Higher DBI values were associated with poorer cognitive and physical performance, which may negatively influence cardiovascular disease (CVD) therapy outcomes.

Purpose The aim was to assess the anticholinergic and sedative drug prevalence and burden in CVD patients.

Method A retrospective observational study was conducted on the Cardiology ward of University Hospital Medical Center. Data were collected from medical records. DBI was used to calculate the exposure, based on the therapy used before the hospital admission. Descriptive and statistical analysis was performed using IBM SPSS® Statistics ver. 22.

Findings A total of 254 patients aged ≥65 were included in the analysis. Patients were comorbid (Charlson Comorbidity Index, mean ± S.D., 3.18 ± 1.63), with the average number of drugs above 6 (6.21 ± 2.78). Anticholinergic or sedative drugs were used by 23 (9.1%) patients, with identified 19 different drugs. The highest frequency was observed for doxazosin (6; 2.4%), sertraline (6; 2.4%), memantine (4; 1.6%), clonazepam (3; 1.2%) and diazepam (3; 1.2%). The majority of patients had only one drug (15; 5.9%), 2 patients (0.8%) used 2, 4 patients (1.6%) used 3, and 2 patients (0.8%) used 4 different drugs with anticholinergic or sedative effects. Patients who were exposed to those drugs had longer length of hospital stay (15.74 vs 9.41 days, p<0.05), and higher total number of drugs (7.61 vs 6.07, p<0.05). The average DBI value equalled 1.11 ± 0.74 (total range 0.33-2.60). DBI <1 was present in 13 (5.1%) patients, and higher DBI≥1 in 10 (4%) patients.

Conclusion The study revealed lower than expected exposure to anticholinergic or sedative drugs. The results could be seen as beneficial, as the minimization of anticholinergic burden in CVD patients is highly recommended.
PB  - Springer Nature
C3  - International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online)
T1  - Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation)
IS  - 459
DO  - 10.1007/s11096-021-01269-4
ER  - 

@conference{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Radovanović, Slavica and Stevanović, Predrag and Miljković, Branislava",
year = "2021",
abstract = "Background Exposure to anticholinergic and sedative drugs have been associated with adverse health outcomes in the elderly population, which can be measured in an individual patient using Drug Burden Index (DBI). Higher DBI values were associated with poorer cognitive and physical performance, which may negatively influence cardiovascular disease (CVD) therapy outcomes.

Purpose The aim was to assess the anticholinergic and sedative drug prevalence and burden in CVD patients.

Method A retrospective observational study was conducted on the Cardiology ward of University Hospital Medical Center. Data were collected from medical records. DBI was used to calculate the exposure, based on the therapy used before the hospital admission. Descriptive and statistical analysis was performed using IBM SPSS® Statistics ver. 22.

Findings A total of 254 patients aged ≥65 were included in the analysis. Patients were comorbid (Charlson Comorbidity Index, mean ± S.D., 3.18 ± 1.63), with the average number of drugs above 6 (6.21 ± 2.78). Anticholinergic or sedative drugs were used by 23 (9.1%) patients, with identified 19 different drugs. The highest frequency was observed for doxazosin (6; 2.4%), sertraline (6; 2.4%), memantine (4; 1.6%), clonazepam (3; 1.2%) and diazepam (3; 1.2%). The majority of patients had only one drug (15; 5.9%), 2 patients (0.8%) used 2, 4 patients (1.6%) used 3, and 2 patients (0.8%) used 4 different drugs with anticholinergic or sedative effects. Patients who were exposed to those drugs had longer length of hospital stay (15.74 vs 9.41 days, p<0.05), and higher total number of drugs (7.61 vs 6.07, p<0.05). The average DBI value equalled 1.11 ± 0.74 (total range 0.33-2.60). DBI <1 was present in 13 (5.1%) patients, and higher DBI≥1 in 10 (4%) patients.

Conclusion The study revealed lower than expected exposure to anticholinergic or sedative drugs. The results could be seen as beneficial, as the minimization of anticholinergic burden in CVD patients is highly recommended.",
publisher = "Springer Nature",
journal = "International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online)",
title = "Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation)",
number = "459",
doi = "10.1007/s11096-021-01269-4"
}

Kovačević, M., Vezmar-Kovačević, S., Radovanović, S., Stevanović, P.,& Miljković, B.. (2021). Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation). in International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online)
Springer Nature.(459).
https://doi.org/10.1007/s11096-021-01269-4

Kovačević M, Vezmar-Kovačević S, Radovanović S, Stevanović P, Miljković B. Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation). in International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online). 2021;(459).
doi:10.1007/s11096-021-01269-4 .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Radovanović, Slavica, Stevanović, Predrag, Miljković, Branislava, "Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation)" in International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online), no. 459 (2021),
https://doi.org/10.1007/s11096-021-01269-4 . .

TY  - JOUR
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
AU  - Miljković, Branislava
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3616
AB  - Background Drug–drug interactions represent one of the causes of adverse therapy outcomes through deteriorated efficacy or safety. However, the true extent of harm related to drug–drug interactions is not well established due to a lack of recognition and understanding. Objective The aim of this study was to investigate the association of potential drug–drug interactions with patients variables recorded at admission. Setting A cross-sectional correlation study was performed on the Cardiology ward of the University Clinical Hospital Center in Belgrade, Serbia. Method Data were retrospectively obtained from medical records and LexiInteract was used as the screening tool for potential drug–drug interactions. Main outcome measure Clinical and laboratory parameters recorded at the patients admission. Results A total of 351 patient records entered the analysis, with the mean age of 70 ± 10 years. The prevalence of potentially relevant drug–drug interactions was 61% (N = 213). After controlling for patient characteristics, nine potential drug–drug interactions were significantly associated with laboratory values outside the range and five potential drug–drug interactions with inadequate clinical parameter values. Potential drug–drug interactions were associated with abnormalities in blood count, metabolic parameters, electrolyte imbalance and renal function parameters. Association with inadequate control of systolic, diastolic blood pressure, as well as heart rhythm was also shown. Conclusion Drug–drug interactions were associated with patients clinical and laboratory findings. Our findings may assist in the identification of patients with increased likelihood of suboptimal therapy outcomes. Generating evidence through post-marketing drug–drug interactions research would lead to improvement in clinical decision-support systems, increased effectiveness and utilization in everyday clinical practice.
PB  - Springer
T2  - International Journal of Clinical Pharmacy
T1  - Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission
VL  - 42
IS  - 1
SP  - 150
EP  - 157
DO  - 10.1007/s11096-019-00951-y
ER  - 

@article{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Radovanović, Slavica and Stevanović, Predrag and Miljković, Branislava",
year = "2020",
abstract = "Background Drug–drug interactions represent one of the causes of adverse therapy outcomes through deteriorated efficacy or safety. However, the true extent of harm related to drug–drug interactions is not well established due to a lack of recognition and understanding. Objective The aim of this study was to investigate the association of potential drug–drug interactions with patients variables recorded at admission. Setting A cross-sectional correlation study was performed on the Cardiology ward of the University Clinical Hospital Center in Belgrade, Serbia. Method Data were retrospectively obtained from medical records and LexiInteract was used as the screening tool for potential drug–drug interactions. Main outcome measure Clinical and laboratory parameters recorded at the patients admission. Results A total of 351 patient records entered the analysis, with the mean age of 70 ± 10 years. The prevalence of potentially relevant drug–drug interactions was 61% (N = 213). After controlling for patient characteristics, nine potential drug–drug interactions were significantly associated with laboratory values outside the range and five potential drug–drug interactions with inadequate clinical parameter values. Potential drug–drug interactions were associated with abnormalities in blood count, metabolic parameters, electrolyte imbalance and renal function parameters. Association with inadequate control of systolic, diastolic blood pressure, as well as heart rhythm was also shown. Conclusion Drug–drug interactions were associated with patients clinical and laboratory findings. Our findings may assist in the identification of patients with increased likelihood of suboptimal therapy outcomes. Generating evidence through post-marketing drug–drug interactions research would lead to improvement in clinical decision-support systems, increased effectiveness and utilization in everyday clinical practice.",
publisher = "Springer",
journal = "International Journal of Clinical Pharmacy",
title = "Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission",
volume = "42",
number = "1",
pages = "150-157",
doi = "10.1007/s11096-019-00951-y"
}

Kovačević, M., Vezmar-Kovačević, S., Radovanović, S., Stevanović, P.,& Miljković, B.. (2020). Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission. in International Journal of Clinical Pharmacy
Springer., 42(1), 150-157.
https://doi.org/10.1007/s11096-019-00951-y

Kovačević M, Vezmar-Kovačević S, Radovanović S, Stevanović P, Miljković B. Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission. in International Journal of Clinical Pharmacy. 2020;42(1):150-157.
doi:10.1007/s11096-019-00951-y .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Radovanović, Slavica, Stevanović, Predrag, Miljković, Branislava, "Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission" in International Journal of Clinical Pharmacy, 42, no. 1 (2020):150-157,
https://doi.org/10.1007/s11096-019-00951-y . .

TY  - JOUR
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
AU  - Miljković, Branislava
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3733
AB  - Objective: Cardiovascular disease (CVD) drugs have been frequently implicated in adverse drug reaction (ADR)-related hospitalizations. Drug-drug interactions (DDIs) are common preventable cause of ADRs, but the impact of DDIs in the CVD population has not been investigated. Hence, the primary aim of the study was to identify DDIs associated with ADRs in CVD patients at hospital admission. The second aim was to develop a simple tool to identify high-risk patients for DDI-related adverse events. Methods: An observational study was conducted on the Cardiology Ward of University Clinical Hospital Center. Data were obtained from medical charts. A clinical panel identified DDIs implicated in ADRs, using LexiInteract database and Drug Interaction Probability Scale. Statistics were performed using PASW 22 (SPSS Inc.). Results: DDIs contributed to hospital admission with a total prevalence of 9.69%. DDI-related ADRs affected mainly cardiac function (heart rate or rhythm, 41.07%); bleeding and effect on blood pressure were equally distributed (17.86%). Non-cardiovascular ADRs were found in 23.21% of DDIs. After admission, 73% of the identified DDIs led to changes in prescription. Prediction ability of calculated DDI adverse event probability scores was rated as good (AUC = 0.80, p < .001). Conclusions: CVD patients are highly exposed to adverse DDIs; about one in ten patients hospitalized with CVD might have a DDI contributing to the hospitalization. Given the high prevalence of CVD, DDI-related harm might be a significant burden worldwide. Identification of patients with high DDI adverse event risk might ease the recognition of DDI-related harm and improve the use of electronic databases in clinical practice.
PB  - Taylor and Francis Ltd
T2  - Current Medical Research and Opinion
T1  - Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items
VL  - 35
IS  - 11
SP  - 1873
EP  - 1883
DO  - 10.1080/03007995.2019.1647021
ER  - 

@article{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Radovanović, Slavica and Stevanović, Predrag and Miljković, Branislava",
year = "2019",
abstract = "Objective: Cardiovascular disease (CVD) drugs have been frequently implicated in adverse drug reaction (ADR)-related hospitalizations. Drug-drug interactions (DDIs) are common preventable cause of ADRs, but the impact of DDIs in the CVD population has not been investigated. Hence, the primary aim of the study was to identify DDIs associated with ADRs in CVD patients at hospital admission. The second aim was to develop a simple tool to identify high-risk patients for DDI-related adverse events. Methods: An observational study was conducted on the Cardiology Ward of University Clinical Hospital Center. Data were obtained from medical charts. A clinical panel identified DDIs implicated in ADRs, using LexiInteract database and Drug Interaction Probability Scale. Statistics were performed using PASW 22 (SPSS Inc.). Results: DDIs contributed to hospital admission with a total prevalence of 9.69%. DDI-related ADRs affected mainly cardiac function (heart rate or rhythm, 41.07%); bleeding and effect on blood pressure were equally distributed (17.86%). Non-cardiovascular ADRs were found in 23.21% of DDIs. After admission, 73% of the identified DDIs led to changes in prescription. Prediction ability of calculated DDI adverse event probability scores was rated as good (AUC = 0.80, p < .001). Conclusions: CVD patients are highly exposed to adverse DDIs; about one in ten patients hospitalized with CVD might have a DDI contributing to the hospitalization. Given the high prevalence of CVD, DDI-related harm might be a significant burden worldwide. Identification of patients with high DDI adverse event risk might ease the recognition of DDI-related harm and improve the use of electronic databases in clinical practice.",
publisher = "Taylor and Francis Ltd",
journal = "Current Medical Research and Opinion",
title = "Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items",
volume = "35",
number = "11",
pages = "1873-1883",
doi = "10.1080/03007995.2019.1647021"
}

Kovačević, M., Vezmar-Kovačević, S., Radovanović, S., Stevanović, P.,& Miljković, B.. (2019). Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. in Current Medical Research and Opinion
Taylor and Francis Ltd., 35(11), 1873-1883.
https://doi.org/10.1080/03007995.2019.1647021

Kovačević M, Vezmar-Kovačević S, Radovanović S, Stevanović P, Miljković B. Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. in Current Medical Research and Opinion. 2019;35(11):1873-1883.
doi:10.1080/03007995.2019.1647021 .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Radovanović, Slavica, Stevanović, Predrag, Miljković, Branislava, "Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items" in Current Medical Research and Opinion, 35, no. 11 (2019):1873-1883,
https://doi.org/10.1080/03007995.2019.1647021 . .

TY  - CONF
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
AU  - Miljković, Branislava
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3259
PB  - Springer
C3  - European Journal of Clinical Pharmacology
T1  - Clinically significant drug-drug interactions in cardiovascular diseases: comparing the prevalence and prescribing patterns between inpatient and outpatient settings
VL  - 75, Suppl. 1
SP  - S38
EP  - S39
DO  - 10.1007/s00228-019-02685-2
ER  - 

@conference{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Radovanović, Slavica and Stevanović, Predrag and Miljković, Branislava",
year = "2019",
publisher = "Springer",
journal = "European Journal of Clinical Pharmacology",
title = "Clinically significant drug-drug interactions in cardiovascular diseases: comparing the prevalence and prescribing patterns between inpatient and outpatient settings",
volume = "75, Suppl. 1",
pages = "S38-S39",
doi = "10.1007/s00228-019-02685-2"
}

Kovačević, M., Vezmar-Kovačević, S., Radovanović, S., Stevanović, P.,& Miljković, B.. (2019). Clinically significant drug-drug interactions in cardiovascular diseases: comparing the prevalence and prescribing patterns between inpatient and outpatient settings. in European Journal of Clinical Pharmacology
Springer., 75, Suppl. 1, S38-S39.
https://doi.org/10.1007/s00228-019-02685-2

Kovačević M, Vezmar-Kovačević S, Radovanović S, Stevanović P, Miljković B. Clinically significant drug-drug interactions in cardiovascular diseases: comparing the prevalence and prescribing patterns between inpatient and outpatient settings. in European Journal of Clinical Pharmacology. 2019;75, Suppl. 1:S38-S39.
doi:10.1007/s00228-019-02685-2 .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Radovanović, Slavica, Stevanović, Predrag, Miljković, Branislava, "Clinically significant drug-drug interactions in cardiovascular diseases: comparing the prevalence and prescribing patterns between inpatient and outpatient settings" in European Journal of Clinical Pharmacology, 75, Suppl. 1 (2019):S38-S39,
https://doi.org/10.1007/s00228-019-02685-2 . .

TY  - CONF
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2990
PB  - Wiley, Hoboken
C3  - Pharmacotherapy
T1  - The prevalence of potential drug-drug interactions in hospital setting: cardiovascular diseases versus comorbidities
VL  - 37
IS  - 6
SP  - e38
EP  - e38
DO  - 10.1002/phar.1964
ER  - 

@conference{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Radovanović, Slavica and Stevanović, Predrag",
year = "2017",
publisher = "Wiley, Hoboken",
journal = "Pharmacotherapy",
title = "The prevalence of potential drug-drug interactions in hospital setting: cardiovascular diseases versus comorbidities",
volume = "37",
number = "6",
pages = "e38-e38",
doi = "10.1002/phar.1964"
}

Kovačević, M., Vezmar-Kovačević, S., Miljković, B., Radovanović, S.,& Stevanović, P.. (2017). The prevalence of potential drug-drug interactions in hospital setting: cardiovascular diseases versus comorbidities. in Pharmacotherapy
Wiley, Hoboken., 37(6), e38-e38.
https://doi.org/10.1002/phar.1964

Kovačević M, Vezmar-Kovačević S, Miljković B, Radovanović S, Stevanović P. The prevalence of potential drug-drug interactions in hospital setting: cardiovascular diseases versus comorbidities. in Pharmacotherapy. 2017;37(6):e38-e38.
doi:10.1002/phar.1964 .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Radovanović, Slavica, Stevanović, Predrag, "The prevalence of potential drug-drug interactions in hospital setting: cardiovascular diseases versus comorbidities" in Pharmacotherapy, 37, no. 6 (2017):e38-e38,
https://doi.org/10.1002/phar.1964 . .

TY  - JOUR
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2874
AB  - Aim: The aim was to describe the type and prevalence of potentially relevant drug-drug interactions (pDDIs) in a population of patients admitted for cardiovascular diseases (CVD), and management strategies for reducing the occurrence of pDDIs. Methods: A retrospective cross-sectional study was performed on Cardiology ward of University Clinical Hospital Center in Belgrade, Serbia. A total of 527 patients, with more than one prescription during hospital stay, were enrolled in this study. Data were obtained from medical records. LexiInteract was used as the screening tool. Results: At least one potentially relevant pDDI was identified in 83.9% of patients. Occurrence was significantly more prevalent in patients with higher number of drugs, multimorbidity, longer length of stay, arrhythmia, heart failure, infectious and respiratory disease. About 13% of pDDIs exposures were accompanied with concurrent renal or liver disease, as an additional risk for DDI manifestation. Among CVD, patients with a history of myocardial infarction possessed the highest additional risk. The most common potential clinical outcome was the effect on cardiovascular system 48.5%, renal function and/or potassium 22.3%, bleeding 9.5%, impaired glucose control 6.8% and digoxin toxicity 4.6%. Main management strategies to avoid X or D class included using paracetamol instead of NSAID or alternative NSAID (38%), alternative antibiotic or antifungal (20.4%), H-2 receptor antagonist instead of PPI (8.3%), avoiding therapeutic duplication (7.3%), and alternative HMG-CoA reductase inhibitor (7%). Heart rate, blood pressure, electrolytes/potassium and blood glucose could have been employed in monitoring for potential consequence of 72.2% C class pDDIs. Conclusions: Use of drug interaction screening tools can be beneficial risk mitigation strategy for potentially relevant pDDIs in CVD patients. DDI screening software could be linked to the patient's laboratory results or clinical data regarding renal or liver function, as an approach to reinforce DDIs alert quality.
PB  - Wiley, Hoboken
T2  - International Journal of Clinical Practice
T1  - The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study
VL  - 71
IS  - 10
DO  - 10.1111/ijcp.13005
ER  - 

@article{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Radovanović, Slavica and Stevanović, Predrag",
year = "2017",
abstract = "Aim: The aim was to describe the type and prevalence of potentially relevant drug-drug interactions (pDDIs) in a population of patients admitted for cardiovascular diseases (CVD), and management strategies for reducing the occurrence of pDDIs. Methods: A retrospective cross-sectional study was performed on Cardiology ward of University Clinical Hospital Center in Belgrade, Serbia. A total of 527 patients, with more than one prescription during hospital stay, were enrolled in this study. Data were obtained from medical records. LexiInteract was used as the screening tool. Results: At least one potentially relevant pDDI was identified in 83.9% of patients. Occurrence was significantly more prevalent in patients with higher number of drugs, multimorbidity, longer length of stay, arrhythmia, heart failure, infectious and respiratory disease. About 13% of pDDIs exposures were accompanied with concurrent renal or liver disease, as an additional risk for DDI manifestation. Among CVD, patients with a history of myocardial infarction possessed the highest additional risk. The most common potential clinical outcome was the effect on cardiovascular system 48.5%, renal function and/or potassium 22.3%, bleeding 9.5%, impaired glucose control 6.8% and digoxin toxicity 4.6%. Main management strategies to avoid X or D class included using paracetamol instead of NSAID or alternative NSAID (38%), alternative antibiotic or antifungal (20.4%), H-2 receptor antagonist instead of PPI (8.3%), avoiding therapeutic duplication (7.3%), and alternative HMG-CoA reductase inhibitor (7%). Heart rate, blood pressure, electrolytes/potassium and blood glucose could have been employed in monitoring for potential consequence of 72.2% C class pDDIs. Conclusions: Use of drug interaction screening tools can be beneficial risk mitigation strategy for potentially relevant pDDIs in CVD patients. DDI screening software could be linked to the patient's laboratory results or clinical data regarding renal or liver function, as an approach to reinforce DDIs alert quality.",
publisher = "Wiley, Hoboken",
journal = "International Journal of Clinical Practice",
title = "The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study",
volume = "71",
number = "10",
doi = "10.1111/ijcp.13005"
}

Kovačević, M., Vezmar-Kovačević, S., Miljković, B., Radovanović, S.,& Stevanović, P.. (2017). The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study. in International Journal of Clinical Practice
Wiley, Hoboken., 71(10).
https://doi.org/10.1111/ijcp.13005

Kovačević M, Vezmar-Kovačević S, Miljković B, Radovanović S, Stevanović P. The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study. in International Journal of Clinical Practice. 2017;71(10).
doi:10.1111/ijcp.13005 .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Radovanović, Slavica, Stevanović, Predrag, "The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study" in International Journal of Clinical Practice, 71, no. 10 (2017),
https://doi.org/10.1111/ijcp.13005 . .

TY  - CONF
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Radovanović, Slavica
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2719
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Predictors of potential clinically significant drug-drug interactions in patients with heart failure.
VL  - 36
IS  - 7
SP  - e87
EP  - e87
DO  - 10.1002/phar.1782
ER  - 

@conference{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Radovanović, Slavica",
year = "2016",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Predictors of potential clinically significant drug-drug interactions in patients with heart failure.",
volume = "36",
number = "7",
pages = "e87-e87",
doi = "10.1002/phar.1782"
}

Kovačević, M., Vezmar-Kovačević, S., Miljković, B.,& Radovanović, S.. (2016). Predictors of potential clinically significant drug-drug interactions in patients with heart failure.. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 36(7), e87-e87.
https://doi.org/10.1002/phar.1782

Kovačević M, Vezmar-Kovačević S, Miljković B, Radovanović S. Predictors of potential clinically significant drug-drug interactions in patients with heart failure.. in Pharmacotherapy. 2016;36(7):e87-e87.
doi:10.1002/phar.1782 .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Radovanović, Slavica, "Predictors of potential clinically significant drug-drug interactions in patients with heart failure." in Pharmacotherapy, 36, no. 7 (2016):e87-e87,
https://doi.org/10.1002/phar.1782 . .

TY  - JOUR
AU  - Stanisavljević, Nataša
AU  - Stojanović, Ljudmila
AU  - Marisavljević, D.
AU  - Đoković, A.
AU  - Dopsaj, Violeta
AU  - Kotur-Stevuljević, Jelena
AU  - Martinović, Jelena
AU  - Memon, Lidija
AU  - Radovanović, Slavica
AU  - Todić, B.
AU  - Lisulov, D.
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2710
AB  - The aim of this study was to evaluate oxidative stress markers and it relations to endothelial damage as risk factor for thrombosis in patients with primary (PAPS) and secondary (SAPS) antiphospholipid syndrome (APS) in correlation to traditional risk factors. Flow-mediated (FMD) and nitroglycerine (NMD)-induced dilation of the brachial artery were studied in 140 APS patients (90 PAPS, 50 SAPS) and 40 controls matched by age, sex, and conventional risk factors for atherosclerosis. Markers of oxidative stress, lipid hydroperoxydes (LOOH), advanced oxidation protein products (AOPP), total sulfhydryl groups (tSHG), and paraoxonase 1 activity (PON1) were determined by spectrophotometric method. Oxidative stress dominates in APS patients. LOOH and AOPP correlate to lipid fractions (p  lt  0.05), unlike PON1, tSHG that correlated to antiphospholipid antibody positivity (p  lt  0.05). FMD was lower in APS patients comparing to controls (p  lt  0.001). Cholesterol is independent variable for FMD impairment in control group (p = 0.011); LOOH in PAPS (p = 0.004); LOOH, aCL, and triglycerides in SAPS patients (p = 0.009, p = 0.049, and p = 0.012, respectively). Combined predictive of aCL and LOOH is better for FMD impairment than LOOH alone in both PAPS and SAPS patients (AUC 0.727, p = 0.001, 95 % CI 0.616-0.837 and AUC 0.824, pE,0.001, 95 % CI 0.690-0.957, respectively). Lipid peroxidation is independent predictor for endothelial dysfunction in APS patients. We demonstrated synergistic effect of aCL and LOOH as risk for endothelial impairment in both PAPS and SAPS patients.
PB  - Springer London Ltd, London
T2  - Clinical Rheumatology
T1  - Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients
VL  - 35
IS  - 10
SP  - 2485
EP  - 2493
DO  - 10.1007/s10067-016-3369-8
ER  - 

@article{
author = "Stanisavljević, Nataša and Stojanović, Ljudmila and Marisavljević, D. and Đoković, A. and Dopsaj, Violeta and Kotur-Stevuljević, Jelena and Martinović, Jelena and Memon, Lidija and Radovanović, Slavica and Todić, B. and Lisulov, D.",
year = "2016",
abstract = "The aim of this study was to evaluate oxidative stress markers and it relations to endothelial damage as risk factor for thrombosis in patients with primary (PAPS) and secondary (SAPS) antiphospholipid syndrome (APS) in correlation to traditional risk factors. Flow-mediated (FMD) and nitroglycerine (NMD)-induced dilation of the brachial artery were studied in 140 APS patients (90 PAPS, 50 SAPS) and 40 controls matched by age, sex, and conventional risk factors for atherosclerosis. Markers of oxidative stress, lipid hydroperoxydes (LOOH), advanced oxidation protein products (AOPP), total sulfhydryl groups (tSHG), and paraoxonase 1 activity (PON1) were determined by spectrophotometric method. Oxidative stress dominates in APS patients. LOOH and AOPP correlate to lipid fractions (p  lt  0.05), unlike PON1, tSHG that correlated to antiphospholipid antibody positivity (p  lt  0.05). FMD was lower in APS patients comparing to controls (p  lt  0.001). Cholesterol is independent variable for FMD impairment in control group (p = 0.011); LOOH in PAPS (p = 0.004); LOOH, aCL, and triglycerides in SAPS patients (p = 0.009, p = 0.049, and p = 0.012, respectively). Combined predictive of aCL and LOOH is better for FMD impairment than LOOH alone in both PAPS and SAPS patients (AUC 0.727, p = 0.001, 95 % CI 0.616-0.837 and AUC 0.824, pE,0.001, 95 % CI 0.690-0.957, respectively). Lipid peroxidation is independent predictor for endothelial dysfunction in APS patients. We demonstrated synergistic effect of aCL and LOOH as risk for endothelial impairment in both PAPS and SAPS patients.",
publisher = "Springer London Ltd, London",
journal = "Clinical Rheumatology",
title = "Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients",
volume = "35",
number = "10",
pages = "2485-2493",
doi = "10.1007/s10067-016-3369-8"
}

Stanisavljević, N., Stojanović, L., Marisavljević, D., Đoković, A., Dopsaj, V., Kotur-Stevuljević, J., Martinović, J., Memon, L., Radovanović, S., Todić, B.,& Lisulov, D.. (2016). Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients. in Clinical Rheumatology
Springer London Ltd, London., 35(10), 2485-2493.
https://doi.org/10.1007/s10067-016-3369-8

Stanisavljević N, Stojanović L, Marisavljević D, Đoković A, Dopsaj V, Kotur-Stevuljević J, Martinović J, Memon L, Radovanović S, Todić B, Lisulov D. Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients. in Clinical Rheumatology. 2016;35(10):2485-2493.
doi:10.1007/s10067-016-3369-8 .

Stanisavljević, Nataša, Stojanović, Ljudmila, Marisavljević, D., Đoković, A., Dopsaj, Violeta, Kotur-Stevuljević, Jelena, Martinović, Jelena, Memon, Lidija, Radovanović, Slavica, Todić, B., Lisulov, D., "Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients" in Clinical Rheumatology, 35, no. 10 (2016):2485-2493,
https://doi.org/10.1007/s10067-016-3369-8 . .

TY  - CONF
AU  - Kovačević, Milena
AU  - Miljković, Branislava
AU  - Vezmar-Kovačević, Sandra
AU  - Radovanović, Slavica
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2451
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Drug-drug interactions assessment: potential to improve therapy outcomes in elderly Serbian patients with cardiovascular disease.
VL  - 35
IS  - 5
SP  - e66
EP  - e66
DO  - 10.1002/phar.1606
ER  - 

@conference{
author = "Kovačević, Milena and Miljković, Branislava and Vezmar-Kovačević, Sandra and Radovanović, Slavica",
year = "2015",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Drug-drug interactions assessment: potential to improve therapy outcomes in elderly Serbian patients with cardiovascular disease.",
volume = "35",
number = "5",
pages = "e66-e66",
doi = "10.1002/phar.1606"
}

Kovačević, M., Miljković, B., Vezmar-Kovačević, S.,& Radovanović, S.. (2015). Drug-drug interactions assessment: potential to improve therapy outcomes in elderly Serbian patients with cardiovascular disease.. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 35(5), e66-e66.
https://doi.org/10.1002/phar.1606

Kovačević M, Miljković B, Vezmar-Kovačević S, Radovanović S. Drug-drug interactions assessment: potential to improve therapy outcomes in elderly Serbian patients with cardiovascular disease.. in Pharmacotherapy. 2015;35(5):e66-e66.
doi:10.1002/phar.1606 .

Kovačević, Milena, Miljković, Branislava, Vezmar-Kovačević, Sandra, Radovanović, Slavica, "Drug-drug interactions assessment: potential to improve therapy outcomes in elderly Serbian patients with cardiovascular disease." in Pharmacotherapy, 35, no. 5 (2015):e66-e66,
https://doi.org/10.1002/phar.1606 . .